WATERTOWN, Mass., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company focused on the discovery ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
In a report released today, Greg Harrison from Scotiabank maintained a Buy rating on Disc Medicine (IRON – Research Report), with a price target of $62.00. The company’s shares closed last ...
The overall quant rating is not an average of the factor grades listed. Instead, it gives greater weight to the metrics with the strongest predictive value.
Jefferies initiated its coverage of hematology-focused biotech Disc Medicine (NASDAQ:IRON) with a buy recommendation on Wednesday, citing the potential of its lead candidate, bitopertin ...
As of October 22, 2024, the average one-year price target for Disc Medicine is $67.04/share ... The firm decreased its portfolio allocation in IRON by 10.93% over the last quarter.
Fintel reports that on October 23, 2024, Jefferies initiated coverage of Disc Medicine (NasdaqGM:IRON) with a Buy recommendation. Analyst Price Forecast Suggests 31.66% Upside As of October 22 ...